

**MEDICINE  
PROBLEMS**

**.uz**

**ISSN 3030-3133**

**TIBBIYOT FANLARINING  
DOLZARB MASALALARI**

**TOPICAL ISSUES OF MEDICAL  
SCIENCES**



**N° 2 (4)**

**2026**



САЙТ: <https://medicineproblems.uz>  
ISSN: 3030-3133

**MEDICINEPROBLEMS.UZ**  
**TIBBIYOT FANLARINING DOLZARB**  
**MASALALARI**

*№ 2 (4)-2026 (mart)*

**TOPICAL ISSUES OF MEDICAL SCIENCES**

**ТОШКЕНТ-2026**

## **BOSH MUHARRIR:**

ISANOVA SHOIRA TULQINOVNA- Tibbiyot fanlari bo'yicha falsafa doktori (PhD), Samarqand davlat tibbiyot universiteti

## **TAHRIR HAY'ATI:**

### *TIBBIYOT FANLARI*

Safarov Zafar Fayzullayevich –tibbiyot fanlari bo'yicha falsafa doktori (PhD), Toshkent pediatriya tibbiyot instituti;

Xakimov Murod Shavkatovich –tibbiyot fanlari doktori, professor, Toshkent tibbiyot akademiyasi;

Mavlanov Alimbay – tibbiyot fanlari doktori, professor, Toshkent tibbiyot akademiyasi;

Ergashev Nasriddin Shamsiddinovich - tibbiyot fanlari doktori, professor, Toshkent pediatriya instituti;

Abdullayeva Nargiza Nurmamatovna - tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti;

Djurabekova Aziza Taxirovna - tibbiyot fanlari doktori, professor, Samarqand davlat tibbiyot universiteti;

Xaydarova Dildora Kadirovna - tibbiyot fanlari doktori, professor, Toshkent tibbiyot akademiyasi;

Ruziboyev Sanjar Abdusalomovich- tibbiyot fanlari doktori, dotsent, Samarqand davlat tibbiyot universiteti;

Sattarov Oybek Toxirovich- tibbiyot fanlari doktori, dotsent, Toshkent tibbiyot akademiyasi;

Niyozov Shuxrat Tashmirovich - tibbiyot fanlari doktori, dotsent, Samarqand davlat tibbiyot universiteti;

Shomurodova Dilnoza Salimovna - tibbiyot fanlari doktori, dotsent, Samarqand davlat tibbiyot universiteti

Tavasharov Bahodir Nazarovich – tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

Xalmetova Feruza Iskandarovna – tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

G'aybiyev Akmaljon Axmadjonovich - tibbiyot fanlari bo'yicha falsafa doktori (PhD), dotsent, Samarqand davlat tibbiyot universiteti;

Qo'ziyev Otabek Juraqulovich – tibbiyot fanlari nomzodi, dotsent, Toshkent pediatriya tibbiyot instituti;

Ergasheva Munisa Yakubovna - tibbiyot fanlari bo'yicha falsafa doktori (PhD), dotsent, Samarqand davlat tibbiyot universiteti;

Ollanova Shaxnoza Sirlibayevna – tibbiyot fanlari nomzodi, Samarqand davlat tibbiyot universiteti;

Safarov Zafar Fayzullayevich – tibbiyot fanlari nomzodi, Toshkent pediatriya tibbiyot instituti;

Xayitov Ilxom Bahodirovich – tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

Alimov Suxrob Usmonovich- tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

Fozilov Uktam Abdurazzokovich - tibbiyot fanlari nomzodi, dotsent, Buxoro davlat tibbiyot instituti;

Raximov Oybek Umarovich – tibbiyot fanlari nomzodi, Toshkent pediatriya instituti;

Sattarov Inayat Saparbayevich – tibbiyot fanlari nomzodi, Toshkent tibbiyot akademiyasi;

Abidov O'tkir O'ktamovich – tibbiyot fanlari nomzodi, Buxoro davlat tibbiyot instituti;

Amonova Zaxro Qaxramon qizi - tibbiyot fanlari nomzodi, Samarqand davlat tibbiyot universiteti.

### *FARMATSEVIKA FANLARI*

Zulfikariyeva Dilnoza Alisherovna - farmatsevtika fanlari doktori (DSc), professor, Toshkent farmatsevtika instituti;

Toshpo‘latova Azizaxon Dilshodovna -  
farmatsevtika fanlari doktori (DSc), professor,  
Toshkent farmatsevtika instituti;

Xusainova Rayxona Ashrafovna -  
farmatsevtika fanlari doktori (DSc), dotsent,  
Toshkent farmatsevtika instituti;

Maksudova Firuza Xurshidovna farmatsevtika  
fanlari doktori (DSc), dotsent, Toshkent  
farmatsevtika instituti;

Ziyamuxamedova Munojot Mirgiasovna -  
farmatsevtika fanlari doktori, Toshkent  
farmatsevtika instituti, dotsent v.b.;

Rizayeva Nilufar Muxutdinovna –  
farmatsevtika fanlari nomzodi, dotsent  
Toshkent farmatsevtika instituti;

---

**TIBBIYOT FANLARINING DOLZARB**

**MASALALARI** elektron jurnali 02.03.2023-  
yilda 132099-sonli guvohnoma bilan  
davlat ro‘yxatidan o‘tkazilgan.

**Muassis:** “SCIENCEPROBLEMS TEAM”  
mas’uliyati cheklangan jamiyati.

**TAHRIRIYAT MANZILI:**

Toshkent shahri, Yakkasaroy tumani, Kichik  
Beshyog‘och ko‘chasi, 70/10-uy. Elektron  
manzil: [scienceproblems.uz@gmail.com](mailto:scienceproblems.uz@gmail.com)

*Article / Original Paper*

## **CURRENT TREATMENT STRATEGIES AND PATHOGENESIS OF STROKE**

**Latibjanov Nizomiddinqori Abdushukur ugli**

Independent researcher of Neurology department of Andijan State Medical Institute

**Shermukhamedova Feruza Kabuljanovna**

DSc, docent of Neurology department of Tashkent State Medical University

**Annotation.** Every year, around 800,000 individuals experience new or recurrent strokes, with most of these being new cases. Approximately 87% are ischemic, 10% reflect intracranial hemorrhage (ICH), and 3% are SAH. Despite a general decrease in stroke incidence during the past 30 years, it is projected that by 2030, an additional 3.4 million US. The pathogenesis of stroke is highly complex, multifactorial, and involves multiple interconnected mechanisms. It includes neurovascular unit dysfunction, hemodynamic disturbances, excitotoxicity, calcium overload, mitochondrial dysfunction, oxidative stress, inflammatory responses, apoptosis, and autophagy. These processes interact dynamically and contribute to neuronal injury and infarct progression. Despite significant advances in understanding these mechanisms, the precise sequence of events and the extent of their interaction remain incompletely elucidated. In particular, the integrated role of metabolic factors—such as calcium-phosphorus homeostasis, lipid metabolism, and hormonal regulation—in the progression and severity of ischemic stroke has not yet been fully clarified. Therefore, stroke pathogenesis remains only partially understood, and further experimental and clinical research is required to better define its molecular mechanisms and to develop more effective, individualized therapeutic strategies.

**Key words:** Ischemic stroke, Stroke pathogenesis, Calcium-phosphorus homeostasis, mineral metabolism, hyperphosphatemia, hyperphosphatemia, vascular calcification, neurovascular dysfunction, atherosclerosis, dyslipidemia, cerebral hemodynamics.

## **INSULT PATOGENEZI VA DAVOLASHGA ZAMONAVIY YONDASHUVLAR**

**Latbijonov Nizomiddinqori Abdushukur o'g'li**

Andijon davlat tibbiyot instituti

nevrologiya kafedrasida mustaqil ilmiy tadqiqotchisi

**Shermuxamedova Feruza Kabiljonovna**

Toshkent davlat tibbiyot universiteti

nevrologiya kafedrasida dotsenti, tibbiyot fanlari doktori

**Annotatsiya.** Har yili 800 000 ga yaqin kishi yangi yoki qayta insultni boshdan kechiradi, bunda aksariyat holatlar ilk bor yuzaga kelgan xurujlar hissasiga to'g'ri keladi. Insultlarning taxminan 87 foizi ishemik, 10 foizi miya ichi qon quyilishi (Intracerebral Hemorrhage, ICH) va qariyb 3 foizi subaraxnoidal qon quyilishi (Subarachnoid Hemorrhage, SAH) dir. So'nggi 30 yil ichida insult bilan kasallanish darajasi umumiy pasayganiga qaramay, 2030-yilga kelib bu ko'rsatkich oshishi taxmin qilinmoqda. Insult patogenezi o'ta murakkab va ko'p omilli jarayon bo'lib, o'zaro bog'liq bo'lgan quyidagi mexanizmlarni o'z ichiga oladi: neyrovaskulyar birlik disfunktsiyasi, gemodinamik buzilishlar, eksaytotoksiklik, kalsiyning ortiqcha to'planishi, mitoxondrial disfunktsiya, oksidativ stress, yallig'lanish reaksiyalari, apoptoz va autofagiya. Bu jarayonlar bir-biri bilan dinamik tarzda o'zaro ta'sirlashib, neyronlarning shikastlanishiga va infarktning avj olishiga sabab bo'ladi. Ushbu mexanizmlarni o'rganishda erishilgan salmoqli yutuqlarga qaramay, hodisalarning aniq ketma-ketligi va ularning o'zaro ta'sir darajasi hali yetarlicha o'rganilmagan. Xususan, kalsiy-fosfor gomeostazi, lipidlar almashinuvi va gormonal boshqaruv kabi metabolik omillarning ishemik insult og'irligining shakllanishi va rivojlanishidagi integrativ roli hozirgi kunga qadar to'liq aniqlanmagan. Shunday qilib, insult patogenezi qisman o'rganilganligicha qolmoqda, bu esa


kasallikning molekulyar mexanizmlarini aniqroq tushunish hamda samarali individuallashtirilgan davolash strategiyalarini ishlab chiqish uchun keyingi eksperimental va klinik tadqiqotlarni o'tkazishni taqozo etadi.

**Kalit so'zlar:** Ishemik insult, insult patogenezi, kalsiy-fosfor gomeostazi, mineral almashinuvi, giperfosfatemiya, qon tomirlar kalsifikatsiyasi, neyrovaskulyar disfunksiya, ateroskleroz, dislipidemiya, serebral gemodinamika.

DOI: <https://doi.org/10.47390/Med-pro/v4i2y2026/N01>

**Introduction.** Stroke is a leading cause of adult-onset disability. Over half of stroke survivors beyond 6 months are dependent on others for at least one activity of daily living. Annually, there are over 12 million incident cases of stroke, of which 65% are ischemic strokes. Patients with stroke with symptomatic steno-occlusive disease have a risk of recurrent stroke of at least 10–15% within 5 years. Globally, stroke accounts for over seven million deaths each year [1]. Modifiable risk factors include blood pressure management, blood glucose and cholesterol control, physical activity, weight management, and environmental exposure such as air pollution[2, 3]. Acute ischemic stroke is a heterogeneous disease with various stroke subtypes, including atherothrombotic infarct involving large vessel occlusions, cardioembolic infarct, lacunar infarct involving penetrating arteries and perforators, subcortical infarct without clear etiology, and infarct of unusual etiology such as hypercoagulable states, vasculitis, genetic disorders, and dissection.

Increasing evidence suggests that the brain is exquisitely sensitive to even short-duration ischemia and that multiple mechanisms are involved in the tissue damage that results from cerebral ischemia. Ischemic stroke initiates a cascade of events, including ATP depletion, ionic dysregulation, the increased release of glutamate and the excess production of free radicals, as well as edema and inflammation; all these events eventually contribute to cell death[4]. In contrast, in intracerebral hemorrhage, oppression and destruction of brain tissue by hematoma is the primary cause of brain injury, but inflammation, coagulation response and the toxicity of the released hemoglobin play a pivotal role as well[5]. Cell death after ischemic stroke has been attributed in the past mainly to necrosis or apoptosis, but recent reports show the involvement of other newly described forms of cell death(Figure 1).



**Fig 1.Overall several death mechanisms in ischemic stroke.**

The modified Rankin scale (mRS) is a functional assessment scale measuring the degree of disability or dependence in patients with stroke. It is a 7-point scale ranging from 0 (no symptoms) to 6 (death)[6] (Table 1). The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurological examination used to assess stroke severity and changes in clinical status. The NIHSS score ranges from 0 to 42, scoring areas including level of consciousness, eye movements (gaze deviation), visual fields, facial weakness, motor strength, limb ataxia and coordination, sensory loss, language function (dysphasia/aphasia), speech clarity (dysarthria), and neglect/inattention (hemispatial neglect) (Table 2) [7]. NIHSS scores of  $\geq 10$  are 73% sensitive and 74% specific for predicting the presence of large vessel occlusion [8].

mRS	Daily function
0	No symptoms
1	No significant disability
2	Slight disability, independent but unable to carry out all previous ADL
3	Moderate disability, can walk independently but requires help with ADL
4	Moderately severe disability, not independent with ADL
5	Severe disability, full-time nursing care
6	Death

ADL activities of daily living


**Table1.** Modified Rankin scale (mRS)

Stroke severity based on NIHSS score

NIHSS score	Stroke severity
0	No stroke symptoms
1-4	Minor stroke
5-15	Moderate stroke
16-20	Moderate to severe stroke
21-42	Severe stroke

**Table2.**Stroke severity score NIHSS

Cerebral collateral circulation represents a complex compensatory vascular network that maintains cerebral perfusion during arterial occlusion. Multiple anatomical pathways—including the anterior and posterior communicating arteries, leptomeningeal collaterals, external carotid artery connections, dural meningeal arteries, ACA–PCA limbic loop pathways, and anterior spinal artery anastomoses—contribute to alternative blood flow supply. The quality of collateral circulation significantly influences tissue viability and clinical outcomes[9]. Well-developed collaterals are associated with preserved distal perfusion and improved prognosis, whereas poor collateral status correlates with larger infarct size and worse neurological outcome. Therefore, assessment of collateral circulation is crucial for prognostication and therapeutic decision-making in ischemic stroke (Figure2).



**Fig.4. Stages of cerebral hypoperfusion.**

Several clinical factors affect the extent of cerebral hypoperfusion in the setting of ischemia. They include extent of hemodynamic impairment and cardiac status, cerebral autoregulatory impairment and extent of compensatory cerebral collateral circulation, presence of metabolic syndrome of hypertension, hyperlipidemia, and insulin resistance, and brain-body interactions affecting blood oxygen carrying capacity and delivery (including coagulation status, anemia, other hematologic disorders, systemic infection and sepsis, renal and hepatic disorders)[2].

The 2026 International Stroke Conference highlighted major advancements in cerebrovascular science and reinforced the importance of global collaboration in improving stroke care. The release of the updated acute ischemic stroke guidelines reflects significant progress in expanding treatment options, including mobile stroke units, broader thrombolysis use, extended eligibility for mechanical thrombectomy, and the inclusion of pediatric stroke care. The conference emphasized equitable healthcare systems, innovative recovery strategies, hypertension management, and the growing role of artificial intelligence in stroke medicine. Overall, ISC26 underscored the continuing evolution of evidence-based stroke management and the critical role of international cooperation in advancing research and clinical outcomes worldwide.

Cerebrovascular mean flow velocities

	Normal MFV (cm/s)
<b>Artery</b>	
ICA siphon	< 70
MCA M1-M2	< 80
ACA A1	< 80
BA	< 50
VA	< 60
PCA	< 50
<b>Arterial stenosis (50%)</b>	
ICA siphon, ACA (A1)	> 90
MCA M1-M2	> 100
BA-VA-PCA	> 70

**Fig.5.** MFV mean flow velocity, ICA internal carotid artery, MCA middle cerebral artery, ACA anterior cerebral artery, BA basilar artery, VA vertebral artery, PCA posterior cerebral artery

Tissue plasminogen activator (tPA), or alteplase, is the gold standard thrombolytic agent given within 4.5 h of stroke symptom onset [1]. Alteplase binds to fibrin, a mesh-like protein in clots and acts within the endogenous fibrinolytic cascade to convert plasminogen to plasmin, the enzyme that dissolves fibrin resulting in clot dissolution. Tissue plasminogen activator (tPA), or alteplase, is the gold standard thrombolytic agent given within 4.5 h of stroke symptom onset . Alteplase binds to fibrin, a mesh-like protein in clots and acts within the endogenous fibrinolytic cascade to convert plasminogen to plasmin, the enzyme

that dissolves fibrin resulting in clot dissolution.

**Conclusion.** Given the complex and multifactorial nature of ischemic stroke, integrating the broader metabolic and vascular framework may enhance understanding of underlying mechanisms. Further experimental and clinical studies are required to clarify its prognostic significance and to support the development of targeted, individualized therapeutic strategies.

**Адабиётлар/Литература/References**

1. Feigin, V.L., et al., World Stroke Organization: Global Stroke Fact Sheet 2025. *Int J Stroke*, 2025. 20(2): p. 132-144.
2. Arboix, A., et al., Nineteen-year trends in risk factors, clinical characteristics and prognosis in lacunar infarcts. *Neuroepidemiology*, 2010. 35(3): p. 231-6.
3. Gasull, T. and A. Arboix, Molecular Mechanisms and Pathophysiology of Acute Stroke: Emphasis on Biomarkers in the Different Stroke Subtypes. *Int J Mol Sci*, 2022. 23(16).
4. Barthels, D. and H. Das, Current advances in ischemic stroke research and therapies. *Biochim Biophys Acta Mol Basis Dis*, 2020. 1866(4): p. 165260.
5. Mao, R., et al., Neuronal Death Mechanisms and Therapeutic Strategy in Ischemic Stroke. *Neurosci Bull*, 2022. 38(10): p. 1229-1247.
6. Broderick, J.P., O. Adeoye, and J. Elm, Evolution of the Modified Rankin Scale and Its Use in Future Stroke Trials. *Stroke*, 2017. 48(7): p. 2007-2012.
7. Mead, G.E., et al., A systematic review and synthesis of global stroke guidelines on behalf of the World Stroke Organization. *Int J Stroke*, 2023. 18(5): p. 499-531.
8. Bathla, G., et al., Advances in Acute Ischemic Stroke Treatment: Current Status and Future Directions. *AJNR Am J Neuroradiol*, 2023. 44(7): p. 750-758.
9. Bugnicourt, J.M., et al., Relation between intracranial artery calcifications and aortic atherosclerosis in ischemic stroke patients. *J Neurol*, 2010. 257(8): p. 1338-43.

# **MEDICINEPROBLEMS.UZ- TIBBIYOT FANLARINING DOLZARB MASALALARI**

*№ 2 (4)-2026 (mart)*

**TOPICAL ISSUES OF MEDICAL SCIENCES**

**TIBBIYOT FANLARINING DOLZARB  
MASALALARI** elektron jurnali 02.03.2023-  
yilda 132099-sonli guvohnoma bilan  
davlat ro'yxatidan o'tkazilgan.  
**Muassis:** "SCIENCEPROBLEMS TEAM"  
mas'uliyati cheklangan jamiyati.

**TAHRIRIYAT MANZILI:**  
Toshkent shahri, Yakkasaroy tumani, Kichik  
Beshyog'och ko'chasi, 70/10-uy. Elektron  
manzil: [scienceproblems.uz@gmail.com](mailto:scienceproblems.uz@gmail.com)